Received Nov 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Inappropriate Dose Administered/an adult received a pediatric dose of Havrix; Inappropriate Dose Administered/an adult received a pediatric dose of Havrix; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of adult use of a child product in a adult patient who received HAV (Havrix 720) for prophylaxis. On 14-NOV-2025, the patient received Havrix 720. On 14-NOV-2025, an unknown time after receiving Havrix 720, the patient experienced adult use of a child product (Verbatim: Inappropriate Dose Administered/an adult received a pediatric dose of Havrix) and underdose (Verbatim: Inappropriate Dose Administered/an adult received a pediatric dose of Havrix). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 19-NOV-2025 The pharmacist had a physician's office contact that an adult received a pediatric dose of Havrix. They were wondering how to proceed (repeat pediatric dose to total adult dose or to revaccinate with adult dose).